SCHEMBL2469015

SCHEMBL2469015

Cc1onc(-c2ccc(F)cc2)c1-c1cn(-c2ccc(C(=O)O)cc2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 6/20 0.47
PTGS2 P35354 2/20 0.43
MAPK14 Q16539 4/20 0.40
CSNK1D P48730 1/20 0.40
MAP4K4 O95819 1/20 0.40
KDM4A O75164 1/20 0.39
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
ADH5 P11766 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK10 P53779 1/20 0.39
MAPK11 Q15759 1/20 0.39
BCL2L1 Q07817 1/20 0.39
BAD Q92934 1/20 0.39
GPBAR1 Q8TDU6 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470837 0.92 BRD4 (0.45) GABRA5PTGS2MAPK14CSNK1DMAP4K4
SCHEMBL2471573 0.90 PTGS2 (0.47) PTGS2MAPK14MEN1ALDH1A1LMNA
SCHEMBL2473712 0.90 PTGS2 (0.48) PTGS2MAPK14CSNK1DMAPK13MAPK12
SCHEMBL2477300 0.89 GABRA5 (0.43) GABRA5PTGS2MAPK14KDM5AKDM4C
SCHEMBL2471768 0.89 GABRA5 (0.50) GABRA5PTGS2MAPK14MAPK13MAPK12
SCHEMBL2472121 0.87 PTGS2 (0.50) PTGS2MAPK14MAPK13MAPK12MAPK10
SCHEMBL2318424 0.86 PTGS2 (0.44) GABRA5PTGS2MAPK14CSNK1DMAP4K4
SCHEMBL2473617 0.85 NPC1 (0.46) PTGS2MAPK14CSNK1DMAPK13MAPK12
SCHEMBL2473840 0.84 MAPK14 (0.45) PTGS2MAPK14CSNK1DMAPK13MAPK12
SCHEMBL2471855 0.84 PTGS2 (0.47) PTGS2MAPK14MAPK13MAPK12MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP claimed
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP disclosed
US-7414061-B2 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US disclosed
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives GABRA5, GABRA4, GABRA1 GABRA5 1/4885PTGS2 3762/4885MAPK14 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.